Ulrike Theidel1, Alexander Kuhlmann, Anja Braem. 1. Herescon Gmbh, Hannover, Centre for Health Economics Research Hannover, Hannover, Department of Health Care Management, Deutsche BKK, Wolfsburg.
Abstract
BACKGROUND: The German Standing Committee on Vaccination Recommendations (Ständige Impfkommission, STIKO) recommends standard vaccination against pneumococcal infections for all persons aged 60 or older, and for all persons of any age with an increased health risk. It is not known how many persons in the target group in Germany have actually been vaccinated. METHOD: We used claims data of a German statutory health insurance (Deutsche BKK) to determine pneumococcal vaccination rates, stratified by age and risk, for the one-year period 1 July 2008 to 30 June 2009. The number of influenza vaccinations in the same period was analyzed for comparison. Because pneumococcal vaccination does not need to be performed annually, the calculated rates are an underestimate of the percentage of persons who have been vaccinated. A simulation model was used to correct for persons vaccinated at earlier times. The vaccination rates were estimated on the basis of various scenarios. RESULTS: Data were obtained on 867 683 persons aged 18 or older. According to an optimistic estimate, the percentage of pneumococcal vaccination in the overall population is 3.75% for persons aged 18-59 and 50.89% for persons aged 60 and above (influenza: 8.80% and 41.15%, respectively). In persons at elevated risk, the rate of vaccination in the presence of at least one risk factor is 12.66% / 54.67% (influenza: 15.66% / 39.96%). In persons with moderate risk, the vaccination rate is 16.02% / 56.75% (influenza: 18.54% / 40.61%); in persons whose elevated risk was high, it is 8.93% / 52.21% (influenza: 7.37%/37.78%). The limitations of this study are the short study period and the inability to define the population at risk unambiguously. CONCLUSION: The rate of pneumococcal vaccination in adults in Germany is too low; at best, it is comparable to that of influenza vaccination. These results should be validated by nationwide monitoring of the pneumococcal vaccination program. For example, questions about pneumococcal vaccination could be included in the GEDA study (German Health Update) that is conducted annually by the Robert Koch Institute.
BACKGROUND: The German Standing Committee on Vaccination Recommendations (Ständige Impfkommission, STIKO) recommends standard vaccination against pneumococcal infections for all persons aged 60 or older, and for all persons of any age with an increased health risk. It is not known how many persons in the target group in Germany have actually been vaccinated. METHOD: We used claims data of a German statutory health insurance (Deutsche BKK) to determine pneumococcal vaccination rates, stratified by age and risk, for the one-year period 1 July 2008 to 30 June 2009. The number of influenza vaccinations in the same period was analyzed for comparison. Because pneumococcal vaccination does not need to be performed annually, the calculated rates are an underestimate of the percentage of persons who have been vaccinated. A simulation model was used to correct for persons vaccinated at earlier times. The vaccination rates were estimated on the basis of various scenarios. RESULTS: Data were obtained on 867 683 persons aged 18 or older. According to an optimistic estimate, the percentage of pneumococcal vaccination in the overall population is 3.75% for persons aged 18-59 and 50.89% for persons aged 60 and above (influenza: 8.80% and 41.15%, respectively). In persons at elevated risk, the rate of vaccination in the presence of at least one risk factor is 12.66% / 54.67% (influenza: 15.66% / 39.96%). In persons with moderate risk, the vaccination rate is 16.02% / 56.75% (influenza: 18.54% / 40.61%); in persons whose elevated risk was high, it is 8.93% / 52.21% (influenza: 7.37%/37.78%). The limitations of this study are the short study period and the inability to define the population at risk unambiguously. CONCLUSION: The rate of pneumococcal vaccination in adults in Germany is too low; at best, it is comparable to that of influenza vaccination. These results should be validated by nationwide monitoring of the pneumococcal vaccination program. For example, questions about pneumococcal vaccination could be included in the GEDA study (German Health Update) that is conducted annually by the Robert Koch Institute.
Authors: G Brenner; H Koch; H Kerek-Bodden; J Heuer; A Lang; A Lang Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2007-08 Impact factor: 1.513
Authors: Andrés de Roux; B Schmöle-Thoma; B Schmöele-Thoma; G R Siber; J G Hackell; A Kuhnke; N Ahlers; S A Baker; A Razmpour; E A Emini; P D Fernsten; W C Gruber; S Lockhart; O Burkhardt; T Welte; H M Lode Journal: Clin Infect Dis Date: 2008-04-01 Impact factor: 9.079
Authors: Isla Ogilvie; Antoine El Khoury; Yadong Cui; Erik Dasbach; John D Grabenstein; Mireille Goetghebeur Journal: Vaccine Date: 2009-06-09 Impact factor: 3.641
Authors: S Ewig; N Birkner; R Strauss; E Schaefer; J Pauletzki; H Bischoff; P Schraeder; T Welte; G Hoeffken Journal: Thorax Date: 2009-05-18 Impact factor: 9.139
Authors: Niklas Schurig; Anton J Beck; Hannes Blankenfeld; Manja Dannenberg; Michael Freitag; Martin Hirte; Vanadis Kamm-Kohl Journal: Dtsch Arztebl Int Date: 2014-04-04 Impact factor: 5.594
Authors: K Albrecht; D Huscher; T Eidner; S Kleinert; S Späthling-Mestekemper; S Bischoff; A Zink Journal: Z Rheumatol Date: 2017-02 Impact factor: 1.372
Authors: M Corcoran; I Vickers; J Mereckiene; S Murchan; S Cotter; M Fitzgerald; M McElligott; M Cafferkey; D O'Flanagan; R Cunney; H Humphreys Journal: Epidemiol Infect Date: 2017-08 Impact factor: 4.434